JP2016517432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517432A5 JP2016517432A5 JP2016502769A JP2016502769A JP2016517432A5 JP 2016517432 A5 JP2016517432 A5 JP 2016517432A5 JP 2016502769 A JP2016502769 A JP 2016502769A JP 2016502769 A JP2016502769 A JP 2016502769A JP 2016517432 A5 JP2016517432 A5 JP 2016517432A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- alkyl
- membered
- phenyl
- membered heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC(CCC(C)C)C*C(C1CCC(*N)CC1)=C Chemical compound CCC(CCC(C)C)C*C(C1CCC(*N)CC1)=C 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790637P | 2013-03-15 | 2013-03-15 | |
| US61/790,637 | 2013-03-15 | ||
| US201361914915P | 2013-12-11 | 2013-12-11 | |
| US61/914,915 | 2013-12-11 | ||
| PCT/US2014/028370 WO2014144100A2 (en) | 2013-03-15 | 2014-03-14 | Sgc stimulators |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017080300A Division JP6267384B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2017080301A Division JP6267385B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2018193191A Division JP6709000B2 (ja) | 2013-03-15 | 2018-10-12 | ｓＧＣ刺激薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016517432A JP2016517432A (ja) | 2016-06-16 |
| JP2016517432A5 true JP2016517432A5 (OSRAM) | 2017-04-20 |
Family
ID=50513493
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502769A Pending JP2016517432A (ja) | 2013-03-15 | 2014-03-14 | ｓＧＣ刺激薬 |
| JP2017080300A Active JP6267384B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2017080301A Active JP6267385B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2018193191A Active JP6709000B2 (ja) | 2013-03-15 | 2018-10-12 | ｓＧＣ刺激薬 |
| JP2020081703A Active JP7072602B2 (ja) | 2013-03-15 | 2020-05-07 | ｓＧＣ刺激薬 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017080300A Active JP6267384B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2017080301A Active JP6267385B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2018193191A Active JP6709000B2 (ja) | 2013-03-15 | 2018-10-12 | ｓＧＣ刺激薬 |
| JP2020081703A Active JP7072602B2 (ja) | 2013-03-15 | 2020-05-07 | ｓＧＣ刺激薬 |
Country Status (23)
| Country | Link |
|---|---|
| US (8) | US9481689B2 (OSRAM) |
| EP (3) | EP2970243B1 (OSRAM) |
| JP (5) | JP2016517432A (OSRAM) |
| KR (3) | KR102502937B1 (OSRAM) |
| CN (5) | CN105408328B (OSRAM) |
| AU (4) | AU2014227862C1 (OSRAM) |
| BR (1) | BR112015023349A2 (OSRAM) |
| CA (1) | CA2907111C (OSRAM) |
| CY (2) | CY1122919T1 (OSRAM) |
| DK (2) | DK2970243T3 (OSRAM) |
| EA (2) | EA033168B1 (OSRAM) |
| ES (3) | ES2966517T3 (OSRAM) |
| HR (2) | HRP20220376T1 (OSRAM) |
| HU (2) | HUE059178T2 (OSRAM) |
| IL (4) | IL285564B2 (OSRAM) |
| LT (2) | LT2970243T (OSRAM) |
| ME (1) | ME03664B (OSRAM) |
| MX (3) | MX384408B (OSRAM) |
| PL (2) | PL2970243T3 (OSRAM) |
| PT (2) | PT2970243T (OSRAM) |
| RS (2) | RS63108B1 (OSRAM) |
| SI (2) | SI3660013T1 (OSRAM) |
| WO (1) | WO2014144100A2 (OSRAM) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1467679B1 (en) | 2001-12-20 | 2015-11-04 | TriVascular, Inc. | Advanced endovascular graft |
| CN103491900B (zh) | 2010-12-23 | 2017-03-01 | 托尔福公司 | 用于二尖瓣修复和替换的系统 |
| EP3964176B1 (en) | 2011-06-21 | 2025-05-14 | Twelve, Inc. | Prosthetic heart valve devices |
| US9763780B2 (en) | 2011-10-19 | 2017-09-19 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
| US11202704B2 (en) | 2011-10-19 | 2021-12-21 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| WO2013059743A1 (en) | 2011-10-19 | 2013-04-25 | Foundry Newco Xii, Inc. | Devices, systems and methods for heart valve replacement |
| CN103974674B (zh) | 2011-10-19 | 2016-11-09 | 托尔福公司 | 人工心脏瓣膜装置、人工二尖瓣和相关系统及方法 |
| US9655722B2 (en) | 2011-10-19 | 2017-05-23 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| US9039757B2 (en) | 2011-10-19 | 2015-05-26 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| EP2797915B1 (en) * | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
| US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
| WO2014047325A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| EP2970243B1 (en) | 2013-03-15 | 2019-11-27 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| CN105246431B (zh) | 2013-05-20 | 2018-04-06 | 托尔福公司 | 可植入心脏瓣膜装置、二尖瓣修复装置以及相关系统和方法 |
| EP3092231B1 (en) * | 2013-12-11 | 2018-06-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
| WO2016044447A1 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
| WO2016044445A2 (en) * | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| EP3194386A2 (en) * | 2014-09-17 | 2017-07-26 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US10047095B2 (en) | 2014-09-17 | 2018-08-14 | Ironwood Pharmaceuticals, Inc. | sGC stimulators |
| IL313498A (en) | 2014-10-06 | 2024-08-01 | Vertex Pharma | Modulators of the cystic fibrosis transmembrane conductance regulator |
| SI3325013T2 (sl) | 2015-07-23 | 2023-11-30 | Bayer Pharma Aktiengesellschaft | Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba |
| JP7111610B2 (ja) | 2015-08-21 | 2022-08-02 | トゥエルヴ， インコーポレイテッド | 埋込可能な心臓弁デバイス、僧帽弁修復デバイス、ならびに関連するシステム及び方法 |
| EA201891315A1 (ru) | 2015-11-30 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | Твердые дисперсии, содержащие стимулятор sgc |
| CA3006764A1 (en) * | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction |
| WO2017122754A1 (ja) | 2016-01-12 | 2017-07-20 | 日本ケミファ株式会社 | 電位依存性ｔ型カルシウムチャネル阻害剤 |
| IL260701B (en) * | 2016-02-01 | 2022-09-01 | Ironwood Pharmaceuticals Inc | Use of certain sgc stimulators and salts thereof in the preparation of medicaments for the treatment of nonalcoholic steatohepatitis (nash) |
| EP3436446B1 (en) | 2016-03-31 | 2023-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN105753783B (zh) * | 2016-04-08 | 2017-12-15 | 李文淏 | 一种合成塞来昔布的方法 |
| US10265172B2 (en) | 2016-04-29 | 2019-04-23 | Medtronic Vascular, Inc. | Prosthetic heart valve devices with tethered anchors and associated systems and methods |
| CN109476686B (zh) * | 2016-07-07 | 2022-01-18 | 赛克里翁治疗有限公司 | sGC刺激剂的磷前药 |
| AU2017292811B2 (en) | 2016-07-07 | 2021-10-21 | Cyclerion Therapeutics, Inc. | Novel processes for preparation of soluble guanylate cyclase stimulators |
| EA201990237A1 (ru) | 2016-07-07 | 2019-08-30 | Сайклерион Терапьютикс, Инк. | Новые способы получения стимуляторов растворимой гуанилатциклазы |
| EP3481820B1 (en) * | 2016-07-07 | 2023-10-18 | Cyclerion Therapeutics, Inc. | Solid forms of an sgc stimulator |
| CR20220309A (es) | 2016-09-02 | 2022-09-16 | Cyclerion Therapeutics Inc | Estimuladores de sgc |
| EA038096B1 (ru) * | 2016-09-23 | 2021-07-06 | Сайклерион Терапьютикс, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH) |
| HRP20211683T1 (hr) | 2016-09-30 | 2022-03-04 | Vertex Pharmaceuticals Incorporated | Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora |
| EP3525779B1 (de) | 2016-10-11 | 2024-06-05 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone |
| EP3525778A1 (de) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| CN110267949A (zh) * | 2016-11-08 | 2019-09-20 | 塞科里昂医疗股份有限公司 | sGC刺激剂 |
| MX2021013639A (es) | 2016-12-09 | 2022-09-30 | Vertex Pharma | Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística. |
| US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
| US10575950B2 (en) | 2017-04-18 | 2020-03-03 | Twelve, Inc. | Hydraulic systems for delivering prosthetic heart valve devices and associated methods |
| US10433961B2 (en) | 2017-04-18 | 2019-10-08 | Twelve, Inc. | Delivery systems with tethers for prosthetic heart valve devices and associated methods |
| US10702378B2 (en) | 2017-04-18 | 2020-07-07 | Twelve, Inc. | Prosthetic heart valve device and associated systems and methods |
| US10792151B2 (en) | 2017-05-11 | 2020-10-06 | Twelve, Inc. | Delivery systems for delivering prosthetic heart valve devices and associated methods |
| US10646338B2 (en) | 2017-06-02 | 2020-05-12 | Twelve, Inc. | Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods |
| US10709591B2 (en) | 2017-06-06 | 2020-07-14 | Twelve, Inc. | Crimping device and method for loading stents and prosthetic heart valves |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US10786352B2 (en) | 2017-07-06 | 2020-09-29 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
| US10729541B2 (en) | 2017-07-06 | 2020-08-04 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| WO2019055859A1 (en) | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| US11897887B2 (en) | 2017-12-19 | 2024-02-13 | Tisento Therapeutics Inc. | sGC stimulators |
| WO2019161534A1 (en) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
| KR102739727B1 (ko) * | 2018-01-10 | 2024-12-05 | 사이클리온 테라퓨틱스, 인크. | 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체 |
| CN108129387B (zh) * | 2018-01-31 | 2020-05-22 | 南京药石科技股份有限公司 | 一种合成2-氮杂二环[4．1．0]庚烷-1-甲酸盐酸盐的制备方法 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| JP7314173B2 (ja) | 2018-04-30 | 2023-07-25 | バイエル アクチェンゲゼルシャフト | 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用 |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| KR20210031931A (ko) | 2018-07-11 | 2021-03-23 | 사이클리온 테라퓨틱스, 인크. | 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도 |
| EP4545072A3 (en) | 2018-12-05 | 2025-07-02 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia |
| CA3123011A1 (en) * | 2018-12-13 | 2020-06-18 | Nxt Biomedical, Llc | Blood oxygenation treatment methods and devices |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| BR102019016950A2 (pt) * | 2019-08-15 | 2021-02-23 | Inst De Pesquisa Ensino Ciencia E Tecnologia Aplicada Inst Galzu | forma de dosagem intrauretral de medicamento; e dispositivo |
| CA3156536A1 (en) * | 2019-10-29 | 2021-05-06 | Albert Thomas Profy | Treatment of diabetic nephropathy with an sgc stimulator |
| WO2021167458A1 (en) | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
| US20230083417A1 (en) | 2020-02-26 | 2023-03-16 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
| CN111440315B (zh) * | 2020-04-28 | 2021-07-02 | 中国科学院长春应用化学研究所 | 一种自修复热塑性聚脲弹性体及其制备方法 |
| CN112142716B (zh) * | 2020-10-29 | 2021-08-31 | 山东新时代药业有限公司 | 一种5元杂芳基取代的吡嗪衍生物及其应用 |
| CN112569179B (zh) * | 2020-12-25 | 2022-12-27 | 上海交通大学医学院附属第九人民医院 | 一种可注射水凝胶体系及其制备方法 |
| CN114957087A (zh) * | 2022-04-13 | 2022-08-30 | 湖南复瑞生物医药技术有限责任公司 | 一种帕罗韦德中间体制备方法 |
| CN115932092A (zh) * | 2022-12-02 | 2023-04-07 | 中国科学院昆明植物研究所 | 玛咖产品中添加有pde-5抑制剂的检测方法与应用 |
| US20240408116A1 (en) * | 2023-06-08 | 2024-12-12 | Ilylt, Llc | Compositions for enhancing sexual pleasure with reduced pharmaceutical load of pde5 inhibitor |
| WO2025038498A2 (en) | 2023-08-15 | 2025-02-20 | Soundbites Public Benefit Corporation | Composition and method for treating hearing loss |
| CN117582909B (zh) * | 2024-01-19 | 2024-04-02 | 天津凯莱英医药科技发展有限公司 | 一种连续生产5-单硝酸异山梨酯的系统和方法 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| EP0192963B1 (de) | 1985-02-27 | 1988-07-20 | Werkzeugmaschinenfabrik Oerlikon-Bührle AG | Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5721365A (en) | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5155137A (en) | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
| EP0605622B1 (en) | 1991-09-24 | 1997-11-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs |
| WO1993011433A1 (en) | 1991-12-05 | 1993-06-10 | Wallac Oy | Luminescent lanthanide chelates |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
| US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5691423A (en) | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| AU685178B2 (en) | 1993-10-08 | 1998-01-15 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US5700830A (en) | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
| US5470862A (en) * | 1995-02-03 | 1995-11-28 | Ohmeda Pharmaceutical Products Division Inc. | Substituted pyrazolyl compounds and methods employing such compounds |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DK0837052T3 (da) | 1995-06-21 | 2007-01-02 | Shionogi & Co | Bicykliske aminoderivater og PGD2-antagonist indeholdende disse |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| WO1998025915A1 (en) | 1996-12-12 | 1998-06-18 | Shionogi & Co., Ltd. | Fused heterocyclic benzenecarboxylic acid amide derivatives and pgd2 antagonists containing the same |
| EP0944614B1 (en) | 1996-12-13 | 2002-09-11 | Shionogi & Co., Ltd. | Benzothiophenecarboxamide derivatives and pgd2 antagonists comprising them |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| HU228111B1 (en) | 1998-07-08 | 2012-11-28 | Sanofi Aventis Deutschland | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| CN1161101C (zh) | 1998-12-17 | 2004-08-11 | 阿尔扎有限公司 | 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统 |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| WO2003022814A1 (en) | 2001-09-07 | 2003-03-20 | Ono Pharmaceutical Co., Ltd. | Indole derivatives |
| US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| DE60115411D1 (de) | 2000-04-12 | 2006-01-05 | Merck Frosst Canada & Co Kirkl | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| MY136316A (en) | 2001-02-13 | 2008-09-30 | Sanofi Aventis Deutschland | Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical. |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| US6511911B1 (en) | 2001-04-03 | 2003-01-28 | Advanced Micro Devices, Inc. | Metal gate stack with etch stop layer |
| WO2003022813A1 (en) | 2001-09-07 | 2003-03-20 | Ono Pharmaceutical Co., Ltd. | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| WO2003097042A1 (en) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Pgd2 receptor antagonist |
| US7534897B2 (en) | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| DE10244810A1 (de) * | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| KR20050055747A (ko) | 2002-10-04 | 2005-06-13 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 염증 질환 치료용의 ｐｇｄ2 수용체 길항제 |
| EP1585511B1 (en) | 2002-12-20 | 2013-01-23 | Amgen Inc. | Asthma and allergic inflammation modulators |
| UA80871C2 (en) * | 2003-04-29 | 2007-11-12 | Pfizer Ltd | 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension |
| EP1479679A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Triazole-derivatives as factor Xa inhibitors |
| KR20060033033A (ko) | 2003-08-04 | 2006-04-18 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출 및ｈｍｇ-ｃｏａ 리덕타제 억제제의 순간 방출을 제공하는제형 |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| US20100144864A1 (en) | 2007-04-05 | 2010-06-10 | Ironwood Pharmaceuticals, Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
| BRPI0816382A2 (pt) | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças |
| JP2011510082A (ja) | 2008-01-24 | 2011-03-31 | メルク・シャープ・エンド・ドーム・コーポレイション | アンジオテンシンｉｉ受容体拮抗薬 |
| BRPI0912345A2 (pt) * | 2008-05-10 | 2019-09-24 | Bayer Schering Pharma Aktiengesellshaft | estimulante de sgc, ativadores sgc e combinações dos mesmos para o tratamento de deficiencia auditiva |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| AU2010218224B2 (en) | 2009-02-26 | 2013-06-27 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP5708644B2 (ja) | 2010-04-27 | 2015-04-30 | 日本電気株式会社 | 情報処理端末およびその制御方法 |
| EA023254B1 (ru) | 2010-05-27 | 2016-05-31 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
| CN103313976B (zh) | 2010-06-30 | 2016-11-23 | 铁木医药有限公司 | sGC刺激物 |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2637659B1 (en) | 2010-11-09 | 2016-05-18 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US9284298B2 (en) * | 2011-04-11 | 2016-03-15 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| CN104125957B (zh) * | 2011-12-21 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的苄基吡唑 |
| EP2797915B1 (en) * | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
| DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
| WO2014047111A1 (en) * | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| WO2014047325A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| EP2970243B1 (en) | 2013-03-15 | 2019-11-27 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| EP3092231B1 (en) | 2013-12-11 | 2018-06-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
-
2014
- 2014-03-14 EP EP14718278.6A patent/EP2970243B1/en active Active
- 2014-03-14 PL PL14718278T patent/PL2970243T3/pl unknown
- 2014-03-14 KR KR1020227004444A patent/KR102502937B1/ko active Active
- 2014-03-14 KR KR1020217004630A patent/KR102362835B1/ko active Active
- 2014-03-14 RS RS20220352A patent/RS63108B1/sr unknown
- 2014-03-14 IL IL285564A patent/IL285564B2/en unknown
- 2014-03-14 BR BR112015023349A patent/BR112015023349A2/pt not_active Application Discontinuation
- 2014-03-14 CN CN201480027900.3A patent/CN105408328B/zh active Active
- 2014-03-14 CN CN201811217263.2A patent/CN109369635B/zh active Active
- 2014-03-14 JP JP2016502769A patent/JP2016517432A/ja active Pending
- 2014-03-14 DK DK14718278.6T patent/DK2970243T3/da active
- 2014-03-14 LT LTEP14718278.6T patent/LT2970243T/lt unknown
- 2014-03-14 ES ES21214096T patent/ES2966517T3/es active Active
- 2014-03-14 WO PCT/US2014/028370 patent/WO2014144100A2/en not_active Ceased
- 2014-03-14 MX MX2018014773A patent/MX384408B/es unknown
- 2014-03-14 LT LTEP19208775.7T patent/LT3660013T/lt unknown
- 2014-03-14 EP EP21214096.6A patent/EP3998260B1/en active Active
- 2014-03-14 DK DK19208775.7T patent/DK3660013T3/da active
- 2014-03-14 RS RS20200218A patent/RS59981B1/sr unknown
- 2014-03-14 KR KR1020157029189A patent/KR102218771B1/ko active Active
- 2014-03-14 CN CN201810569286.3A patent/CN108912111B/zh active Active
- 2014-03-14 PT PT147182786T patent/PT2970243T/pt unknown
- 2014-03-14 EP EP19208775.7A patent/EP3660013B1/en active Active
- 2014-03-14 EA EA201890641A patent/EA033168B1/ru unknown
- 2014-03-14 ME MEP-2020-40A patent/ME03664B/me unknown
- 2014-03-14 SI SI201431948T patent/SI3660013T1/sl unknown
- 2014-03-14 HU HUE19208775A patent/HUE059178T2/hu unknown
- 2014-03-14 CN CN201811217841.2A patent/CN110016020B/zh active Active
- 2014-03-14 ES ES19208775T patent/ES2911276T3/es active Active
- 2014-03-14 HR HRP20220376TT patent/HRP20220376T1/hr unknown
- 2014-03-14 EA EA201591743A patent/EA031746B1/ru unknown
- 2014-03-14 PL PL19208775T patent/PL3660013T3/pl unknown
- 2014-03-14 HR HRP20200276TT patent/HRP20200276T1/hr unknown
- 2014-03-14 HU HUE14718278A patent/HUE048543T2/hu unknown
- 2014-03-14 CA CA2907111A patent/CA2907111C/en active Active
- 2014-03-14 SI SI201431503T patent/SI2970243T1/sl unknown
- 2014-03-14 PT PT192087757T patent/PT3660013T/pt unknown
- 2014-03-14 AU AU2014227862A patent/AU2014227862C1/en active Active
- 2014-03-14 CN CN201811216402.XA patent/CN109384778B/zh active Active
- 2014-03-14 ES ES14718278T patent/ES2774295T3/es active Active
- 2014-03-14 US US14/775,954 patent/US9481689B2/en active Active
- 2014-03-14 MX MX2015012473A patent/MX361208B/es active IP Right Grant
-
2015
- 2015-09-11 MX MX2021008281A patent/MX2021008281A/es unknown
- 2015-09-16 IL IL24164115A patent/IL241641B/en active IP Right Grant
-
2016
- 2016-07-21 US US15/215,628 patent/US9586937B2/en active Active
- 2016-08-24 US US15/245,697 patent/US10183021B2/en active Active
-
2017
- 2017-01-16 US US15/406,994 patent/US20170137439A1/en not_active Abandoned
- 2017-01-16 US US15/406,959 patent/US10517874B2/en active Active
- 2017-04-14 JP JP2017080300A patent/JP6267384B2/ja active Active
- 2017-04-14 JP JP2017080301A patent/JP6267385B2/ja active Active
-
2018
- 2018-10-12 JP JP2018193191A patent/JP6709000B2/ja active Active
- 2018-11-02 US US16/178,771 patent/US10639308B2/en active Active
-
2019
- 2019-05-22 AU AU2019203606A patent/AU2019203606B9/en active Active
- 2019-11-14 IL IL270646A patent/IL270646B/en active IP Right Grant
-
2020
- 2020-02-27 CY CY20201100188T patent/CY1122919T1/el unknown
- 2020-03-13 US US16/817,830 patent/US11207323B2/en active Active
- 2020-05-07 JP JP2020081703A patent/JP7072602B2/ja active Active
- 2020-12-23 IL IL279695A patent/IL279695B/en unknown
-
2021
- 2021-06-24 AU AU2021204292A patent/AU2021204292B2/en active Active
- 2021-12-20 US US17/556,213 patent/US20230106002A1/en active Pending
-
2022
- 2022-04-13 CY CY20221100280T patent/CY1125178T1/el unknown
-
2023
- 2023-04-04 AU AU2023202058A patent/AU2023202058B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016517432A5 (OSRAM) | ||
| JP2019526582A5 (OSRAM) | ||
| HRP20200276T1 (hr) | Stimulatori sgc | |
| RU2013125480A (ru) | Стимуляторы sgc | |
| JP2016540017A5 (OSRAM) | ||
| JP2015503505A5 (OSRAM) | ||
| JP2015508749A5 (OSRAM) | ||
| JP2016537389A5 (OSRAM) | ||
| RU2017110211A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
| JP2015529235A5 (OSRAM) | ||
| RU2014114466A (ru) | ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА | |
| JP2015503504A5 (OSRAM) | ||
| JP2017514855A5 (OSRAM) | ||
| RU2016141647A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2016535784A5 (OSRAM) | ||
| JP2013527170A5 (OSRAM) | ||
| JP2016512505A5 (OSRAM) | ||
| JP2017528486A5 (OSRAM) | ||
| JP2013526494A5 (OSRAM) | ||
| JP2013533318A5 (OSRAM) | ||
| TW201808284A (zh) | 用於治療或預防高尿酸血症或痛風的化合物及其用途 | |
| JP2017529389A5 (OSRAM) | ||
| JP2016510326A5 (OSRAM) | ||
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| RU2018131440A (ru) | Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания |